Exploring the Multifaceted Landscape of Atopic Dermatitis Care at the 2024 AAD Meeting

Christopher Bunick, MD, PhD, reviews benchmarks for optimal outcomes in patients with atopic dermatitis and compares treatments available.

Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.

Ruth Ann Vleugels, MD, MPH, MBA, shares insights that she gives her own residents on JAK inhibitor selection, risks, benefits, and data available.

Ruth Ann Vleugels, MD, MPH, MBA, delves into patient-specific considerations and action plans when on a JAK inhibitor, including shingles prevention and management.

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.